• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MTEX

    Mannatech Incorporated

    Subscribe to $MTEX
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through network marketing channels and a website. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.

    IPO Year:

    Exchange: NASDAQ

    Website: mannatech.com

    Recent Analyst Ratings for Mannatech Incorporated

    DatePrice TargetRatingAnalyst
    See more ratings

    Mannatech Incorporated Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    Mannatech Incorporated Leadership Updates

    Live Leadership Updates

    See more
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

      Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr

      3/13/24 7:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Results of Annual Shareholders' Meeting

      Mannatech, Incorporated (NASDAQ:MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 6, 2023. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting and David Johnson, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2022 and the first quarter of 2023. There were 1,872,422 outstanding shares of Mannatech's common stock as of April 20, 2023 entitled to vote and 1,270,511 shares, or approximately 67.9% represe

      6/8/23 8:22:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Results of Annual Shareholders' Meeting

      Mannatech, Incorporated (NASDAQ:MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 14, 2022. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting and David Johnson, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2021 and the first quarter of 2022. There were 1,949,716 outstanding shares of Mannatech's common stock as of April 14, 2022 entitled to vote and 1,295,936 shares, or approximately 66.5% represen

      6/17/22 5:27:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Results of Annual Shareholders' Meeting

      Mannatech, Incorporated (NASDAQ:MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 15, 2021. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting and David Johnson, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2020 and the first quarter of 2021. There were 2,063,280 outstanding shares of Mannatech's common stock as of April 16, 2021 entitled to vote and 1,450,658 shares, or approximately 70.3% represen

      6/21/21 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    Mannatech Incorporated Financials

    Live finance-specific insights

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2024

      Q1 2024 EPS of $0.63 vs. $0.32 in Q1 2023 Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2024. First Quarter Highlights Net sales for the quarter ended March 31, 2024 were $29.4 million, as compared to $34.1 million for the same period in 2023, a decrease of $4.7 million, or 13.8%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $3.9 million, or 11.3%, and unfavorable foreign exchange caused a $0.8 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principal

      5/14/24 12:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023

      Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended December 31, 2023. Fourth Quarter Highlights Fourth quarter 2023 net sales were $32.7 million, a decrease of $1.6 million, or 4.7%, as compared to $34.3 million in the fourth quarter of 2022. Gross profit as a percentage of net sales improved to 75.4% as compared to 69.0% for the same period in 2022. Reduced supply chain shipping costs more than offset price increases in certain raw materials. Operating loss in the fourth quarter was $0.9 million, improved from an operating loss

      3/28/24 7:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Third Quarter End 2023 Financial Results

      Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2023. Third Quarter End Results Third quarter net sales for 2023 were $32.6 million, a decrease of $2.9 million, or 8.3%, as compared to $35.5 million in the third quarter of 2022. Our net sales decreased 8.5% on a constant dollar basis (see Non-GAAP Measures, below) however, foreign exchange increased GAAP net sales by $0.1 million, mostly due to the strengthening of the Korean Won. Third quarter operating income for 2023 was $0.2 million as compared to operating income of $1.4 million for the th

      11/7/23 6:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Second Quarter End 2023 Financial Results

      Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2023. Second Quarter End Results Second quarter net sales for 2023 were $32.6 million, a decrease of $2.4 million, or 6.8%, as compared to $35.0 million in the second quarter of 2022. Our net sales decreased 4.0% on a constant dollar basis (see Non-GAAP Measures, below) as foreign exchange decreased GAAP net sales by $1.0 million, mostly due to the decline of the Korean Won and Japanese Yen. Second quarter operating loss for 2023 was $1.0 million as compared to operating income of $0.9 million fo

      8/14/23 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Declares First Quarter 2023 Dividend

      Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend of $0.20 per share of common stock, payable on Thursday, June 29, 2023, to shareholders of record at the close of business on Thursday, June 15, 2023. The dividend demonstrates a commitment to rewarding shareholders and encouraging long-term investment in Mannatech's common stock. Alfredo "Al" Bala, President and CEO of Mannatech, said, "Mannatech is fully committed to delivering value to our shareholders." About Mannatech Mannatech, Incorporated is committed to transforming lives through the

      5/25/23 7:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Fourth Quarter 2022 Financial Results

      Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2022. Quarter End Results Fourth quarter net sales for 2022 were $34.3 million, a decrease of $5.2 million, or 13.2%, as compared to $39.5 million in the fourth quarter of 2021. During the fourth quarter, the company's net sales declined 5.1% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $3.2 million in net sales as compared to the fourth quarter of 2021. The fourth quarter of 2022, tax provision was $3.4 millio

      3/17/23 3:04:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Declares Fourth Quarter 2022 Dividend

      Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend of $0.20 per share of common stock, payable on Thursday, March 30, 2023, to shareholders of record at the close of business on Thursday, March 16, 2023. The dividend demonstrates a commitment to rewarding shareholders and encouraging long-term investment in Mannatech's common stock. Alfredo "Al" Bala, President and CEO of Mannatech, said, "Mannatech is fully committed to delivering value to our shareholders." About Mannatech Mannatech, Incorporated is committed to transforming lives through the d

      3/6/23 6:13:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    Mannatech Incorporated Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Fourth Quarter 2024 Financial Results

      Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2024. Quarter End Results Fourth quarter net sales for 2024 were $29.0 million, a decrease of $3.7 million, or 11.3%, as compared to $32.7 million in the fourth quarter of 2023. During the fourth quarter, the company's net sales declined 9.2% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.7 million in net sales as compared to the fourth quarter of 2023. Gross profit as a percentage of net sales improved to 80

      3/26/25 6:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Mannatech Reports Financial Results for First Quarter 2024

      Q1 2024 EPS of $0.63 vs. $0.32 in Q1 2023 Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2024. First Quarter Highlights Net sales for the quarter ended March 31, 2024 were $29.4 million, as compared to $34.1 million for the same period in 2023, a decrease of $4.7 million, or 13.8%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $3.9 million, or 11.3%, and unfavorable foreign exchange caused a $0.8 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principal

      5/14/24 12:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Charting New Paths: Mannatech Expanding with Thailand Office, Grand Opening, September 2024

      Mannatech, Incorporated (NASDAQ:MTEX), a leading global health and wellness company committed to transforming lives through Glycan technology, is thrilled to announce a significant milestone in its expansion efforts. With a steadfast commitment to empowering individuals and communities through innovative health solutions, Mannatech is excited to announce its continued expansion into the ASEAN region, with the official launch into the Thailand market. This opening will bring Mannatech's global presence to 26 markets. ^ Existing and future Mannatech Associates eagerly anticipate the official launch in Thailand on June 17, 2024. During the soft opening, individuals will be able to register

      4/24/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023

      Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended December 31, 2023. Fourth Quarter Highlights Fourth quarter 2023 net sales were $32.7 million, a decrease of $1.6 million, or 4.7%, as compared to $34.3 million in the fourth quarter of 2022. Gross profit as a percentage of net sales improved to 75.4% as compared to 69.0% for the same period in 2022. Reduced supply chain shipping costs more than offset price increases in certain raw materials. Operating loss in the fourth quarter was $0.9 million, improved from an operating loss

      3/28/24 7:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    Mannatech Incorporated SEC Filings

    See more
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Mannatech Incorporated

      DEF 14A - MANNATECH INC (0001056358) (Filer)

      4/22/25 5:01:03 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Mannatech Incorporated

      DEFA14A - MANNATECH INC (0001056358) (Filer)

      4/22/25 4:56:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      3/25/25 7:07:30 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      11/26/24 4:30:14 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      11/12/24 4:31:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      11/12/24 4:28:27 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

      8-K - MANNATECH INC (0001056358) (Filer)

      9/27/24 4:36:30 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

      8-K - MANNATECH INC (0001056358) (Filer)

      8/22/24 4:38:52 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    Mannatech Incorporated Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Toth Robert

      4/A - MANNATECH INC (0001056358) (Issuer)

      3/17/25 1:23:48 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Fredrick J Stanley was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 0.76% to 356,975 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:18 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Toth Robert was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 3% to 91,130 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Jobe Larry A was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 5% to 57,407 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:36:57 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Robbins Kevin Andrew was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 14% to 21,443 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:36:46 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Rameson Tyler was granted 2,686 shares, increasing direct ownership by 0.90% to 301,883 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:15:02 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director John Seifrick A was granted 2,686 shares, increasing direct ownership by 43% to 8,956 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:12:15 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Toth Robert

      4 - MANNATECH INC (0001056358) (Issuer)

      11/22/24 6:11:27 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Jobe Larry A sold $126,232 worth of Common Stock Par Value $0.0001 Per Share (16,288 units at $7.75), decreasing direct ownership by 23% to 54,721 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:46:20 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    Mannatech Incorporated Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech, Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/4/22 2:19:54 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care